Bakx Therapeutics, Inc. — Form D

Bakx Therapeutics, Inc. of BEARSVILLE, NY, a company, filed a Form D exempt-offering notice with the SEC on 2021-09-07. The offering totals $34.3M, of which $20.3M was reported sold. Industry: Biotechnology.

Offering

Filed: 2021-09-07
Form: D
Accession: 0001104659-21-113036
Industry: Biotechnology
Exemptions: 06b
Total offering: $34.3M
Amount sold: $20.3M
Remaining: $14.0M
Investors: 3
Date of first sale: 2021-08-20
Security types: equity
Revenue range: Decline to Disclose
SEC file number: 021-412464

Issuer

Name: Bakx Therapeutics, Inc.
CIK: 0001876494
Entity type: Corporation
Jurisdiction: DELAWARE
Incorporated: 2020
Address: 551 MT GUARDIAN RD EXT, BEARSVILLE, NY, 12409
Phone: (718) 419-5221

Officers, directors & promoters (12)

Name	Role	Location
Sree Kant	Director	Bearsville, NY
Phillippe Lopes-Fernandes	Director	Boulonge-Billancourt, I0
Yibing Shan	Director	Bearsville, NY
Jessie English	Executive Officer	Bearsville, NY
Ervis Gavathiotis	Executive Officer	Bearsville, NY
Sree Kant	Executive Officer	Bearsville, NY
Loren Walensky	Executive Officer	Cambridge, MA
Jessie English	Promoter	Bearsville, NY
Ervis Gavathiotis	Promoter	Bearsville, NY
Sree Kant	Promoter	Bearsville, NY
Frances Toneguzzo	Promoter	Bearsville, NY
Loren Walensky	Promoter	Cambridge, MA

More